Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1

Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1

BackgroundGalectin-3 (Gal-3) is a β-galactoside-binding lectin that is highly expressed within the tumor microenvironment of aggressive cancers and has been suggested to predict a poor response to immune checkpoint therapy with the anti-PD-1 monoclonal antibody pembrolizumab. We aimed to assess if t...

Full description

Bibliographic Details
Main Authors: Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slack
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
PD-1 - PDL-1 axis
galectin-3 (Gal3)
atezolizumab
pembrolizumab
computational chemistry
immuno-oncology
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1250559/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1250559/full

Similar Items